TAKE A LOOK AT WHICH REPORT YOUR PORTFOLIO'S BEEN MISSING...

Shareholders Foundation offers real-time reporting of class action exposure on a per transaction basis,
including the documents you will need for claim filing and settlement recovery.
Start Monitoring Your Investments

Dendreon Corporation Under Long Term Investor Investigation

  • If you are purchased Dendreon Corporation (NASDAQ: DNDN) shares prior to January 2011 and presently continue to hold those NASDAQ:DNDN shares, you have certain options and you should contact the Shareholders Foundation, Inc.

  • To have your information reviewed for options and to receive notifications about this investigation, please send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.

Investigation Overview

Company
Dendreon Corporation
Security
NASDAQ: DNDN

Summary

San Diego, Aug 15, 2011 (Shareholders Foundation) -- An investigation on behalf of current long term investors of Dendreon Corporation (NASDAQ: DNDN) over possible breaches of fiduciary duties by certain directors and officers of Dendreon Corp. was announced.

The investigation follows a lawsuit filed for investors who purchased DNDN common stock only between January 7, 2011 and August 3, 2011 over alleged violations of Federal Securities Laws by Dendreon Corporation.
The investigation by a law firm on behalf of current long term investors in stock Dendreon (NASDAQ: DNDN) concerns whether certain current and/or former officers and members of Dendreon board of directors and executive officers can be held liable in connection with the alleged Securities Laws violations in the lawsuit by investors who purchased DNDN stock between January 7, 2011 and August 3, 2011. According to the complaint filed in the United States District Court for the Western District of Washington the plaintiff alleges on behalf of purchasers of the securities of Dendreon (DNDN) between January 7, 2011 and August 3, 2011, that Dendreon Corp. certain of its officers violated the Securities Exchange Act of 1934 by making a series of materially false and misleading statements related to Dendreon's business and operations.

Shares of Dendreon Corporation (Public, NASDAQ: DNDN) rose from as low as $2.61 in March 09 to as high as $54.06 in April 2010.

NASDAQ: DNDN stocks fell from over $41 per share in the beginning in July 2011 to under $12 on Thursday, August 4, after Dendreon Corp withdrawal of its sales forecasts for its prostate cancer therapy Provenge. On, August 3, 2011, Dendreon Reported its Second Quarter 2011 Financial Results. Among other things, Dendreon said that it is withdrawing its previous guidance of $350-400 million in revenue for 2011 and currently expects modest quarter over quarter revenue growth for the remainder of this year.

Shares of Dendreon (NASDAQ:DNDN) fell from a close of $35.84 per share on August 3, 2011 to $11.52 during Thursdays trading.

Start Monitoring Your Investments